a16z Podcast: The Science and Business o...

Will we have one AI assistant that does everything, or an entire network of agents that know different parts of our lives? David Pawlan, creator of Assistant Benchmark, returns with Anish Acharya and Josh Elman to take stock of how quickly the agent landscape has changed.David ha ... Show More

This interview with Stripe cofounders John and Patrick Collison originally aired on TBPN. They discuss Stripe's 34% growth and new employee tender offer, how agent commerce and stablecoins may require high-throughput blockchains built for millions of transactions per second, and ... Show More

Anish Acharya speaks with Peter Yang, creator and product lead at Roblox, about how personal AI agents are replacing the apps we open every day, why coding agents feel like slot machines, and what happens when the cost of building software drops to near zero. They discuss why fut ... Show More

Can AI help us find cures for diseases we've never been able to treat? Nicolai Tangen speaks with Vasant 'Vas' Narasimhan, CEO of Novartis, about pioneering pharmaceutical innovation. They explore breakthrough cell and gene therapies, AI partnerships with leading tech companies, ... Show More

Bringing new drugs to market is a costly, time-consuming endeavor. On top of that, most medicines fail at some point in the research and development phase. Sarah Guo is joined by Sajith Wickramasekara, co-founder and CEO of Benchling, a company that has not only become the centra ... Show More

<p>Philip Tagari, Chief Scientific Officer of insitro, joins Vijay Pande, founding general partner at a16z Bio + Health.</p><p>Together, they discuss the transformative power of drugs in changing human health—and history. They also reflect on the evolution of the drug discovery p ... Show More

Can science prevail against this more turbulent backdrop of the Trump administration? Yahoo Finance executive editor Brian Sozzi talks at length with Novartis CEO Vas Narasimhan. Narasimhan has led the drug giant since 2018, doing deals that have expanded the company’s pipeline i ... Show More

<p>What’s next for cancer treatment and personalized medicine? How is AI reshaping the future of drug discovery? And can Europe keep pace with China’s rapid rise in health care innovation? In this episode, Nicolai welcomes Thomas Schinecker, CEO of Roche, one of the world’s large ... Show More

"Pharmaceutical Breakthroughs: The Cutting Edge of Biotechnology" - In this episode, we dive deep into the revolutionary world of biotechnology and its transformative impact on pharmaceuticals. Discover how cutting-edge innovations are reshaping drug development, accelerating vac ... Show More

In this episode of "Driving Digital in Biopharma," host Tom Lehmann welcomes Morrey Atkinson, the Chief Technology and Operations Officer at Vertex Pharmaceuticals. With a rich background in process development and manufacturing within the pharmaceutical industry, Morrey shares h ... Show More

On this episode of the a16z Bio Clubhouse Show, a16z general partners Vineeta Agarwala, Jorge Conde, Julie Yoo, and Vijay Pande, along with a16z cofounder Marc Andreessen, talk to guest Anne Wojcicki, CEO of 23andme. The conversation covers the shifting trends and perceptions at ... Show More

GSK’s Chief Digital and Technology Officer Shobie Ramakrishnan discusses how the company is leveraging AI and data models for vaccine development and drug discovery in this episode of Bloomberg Intelligence’s Tech Disruptors podcast. BI’s Health-Care Analyst Sam Fazeli and Techno ... Show More